12 completed, 5 recruiting, 2 active not recruiting, 2 enrolling by invitation. 21 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) PGN-EDODM1 - Myotonic Dystrophy 1 | Phase 2 | Recruiting | PepGen Inc | 48 | 2025-12-23 | 2026-03-30 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 SAR446268 - Myotonic Dystrophy | Phase 1 / Phase 2 | Recruiting | Sanofi | 32 | 2025-07-23 | 2026-09-21 |
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I VX-670 - Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 44 | 2025-04-28 | 2026-10-14 |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 PGN-EDODM1, Placebo - Myotonic Dystrophy 1 | Phase 2 | Recruiting | PepGen Inc | 24 | 2024-12-10 | 2026-07-29 |
| Study of ATX-01 in Participants With DM1 ATX-01, Placebo - Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Recruiting | ARTHEx Biotech S.L. | 56 | 2024-10-15 | 2026-02-10 |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy SRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection - Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Enrolling by invitation | Sarepta Therapeutics, Inc. | 78 | 2024-03-04 | 2026-10-05 |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) VX-670, Placebo - Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 47 | 2024-02-20 | 2026-08-20 |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 DYNE-101, Placebo - Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | Active not recruiting | Dyne Therapeutics | 127 | 2022-09-05 | 2026-09-23 |
| Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Placebo, AOC 1001 - DM1, Muscular Dystrophies | Phase 2 | Completed | Avidity Biosciences, Inc. | 37 | 2022-08-04 | 2026-09-11 |
| Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients AOC 1001, Placebo - DM1, Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Completed | Avidity Biosciences, Inc. | 39 | 2021-10-28 | 2026-09-28 |
| Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy Tideglusib - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Recruiting | AMO Pharma Limited | 76 | 2021-08-23 | 2025-05-28 |
| Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Pitolisant Oral Tablet, Placebo oral tablet - Myotonic Dystrophy 1, Excessive Daytime Sleepiness | Phase 2 | Completed | Harmony Biosciences Management, Inc. | 30 | 2021-06-28 | 2026-09-04 |
| Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Tideglusib, Placebo - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Completed | AMO Pharma Limited | 56 | 2021-03-03 | 2025-10-08 |
| Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Tideglusib - Myotonic Dystrophy 1 | Phase 2 | Completed | AMO Pharma Limited | 16 | 2016-07-20 | 2025-09-11 |
| A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 IONIS-DMPKRx, Placebo - Myotonic Dystrophy Type 1 | Phase 1 / Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 48 | 2014-12-01 | 2022-12-06 |
| Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM) Mexiletine, Placebo - Non Dystrophic Myotonia | Phase 2 | Completed | Radboud University Medical Center | 30 | 2014-01-01 | 2016-01-26 |
| Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 Mexiletine, Placebo - Myotonic Dystrophy | Phase 2 | Completed | University of Rochester | 42 | 2011-06-01 | 2018-06-19 |
| Methylphenidate in Myotonic Dystrophy Type 1 Methylphenidate, Placebo - Dystrophia Myotonica 1 | Phase 2 / Phase 3 | Completed | Laval University | 28 | 2008-06-01 | 2011-08-23 |
| Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 rhIGF-I/rhIGFBP-3, placebo - Myotonic Dystrophy Type 1 | Phase 2 | Completed | Insmed Incorporated | 69 | 2007-12-01 | 2022-01-06 |
| Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) SomatoKine/IPLEX - Myotonic Dystrophy | Phase 1 / Phase 2 | Completed | University of Rochester | 17 | 2005-11-01 | 2012-06-25 |
Showing 20 of 21. Sign in to see all of them.
Myotonic Dystrophy (20) · Neuromuscular Diseases (5) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Muscular Diseases (4) · Muscular Disorders, Atrophic (4) · Muscular Dystrophies (4) · Musculoskeletal Diseases (4) · Nervous System Diseases (4) · Disorders of Excessive Somnolence (3) · Neurodegenerative Diseases (3) · Myotonia (2) · Potassium aggravated myotonia (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Muscular Diseases (17) · Musculoskeletal Diseases (17) · Nervous System Diseases (17) · Neurodegenerative Diseases (17) · Genetic Diseases, Inborn (16) · Heredodegenerative Disorders, Nervous System (16) · Muscular Disorders, Atrophic (16) · Muscular Dystrophies (16) · Neuromuscular Diseases (16) · Dyssomnias (3) · Mental Disorders (3) · Sleep Disorders, Intrinsic (3) · Sleep Wake Disorders (3)
tideglusib (3) · Mexiletine (2) · IGF-I-IGFBP-3 complex (1) · Insulin-Like Growth Factor I (1) · Methylphenidate (1) · Sodium Chloride (1) · pitolisant (1) · somatoKine (1)
AMO Pharma Limited (3) · Avidity Biosciences, Inc. (2) · PepGen Inc (2) · University of Rochester (2) · Vertex Pharmaceuticals Incorporated (2) · ARTHEx Biotech S.L. (1) · Dyne Therapeutics (1) · Harmony Biosciences Management, Inc. (1) · Insmed Incorporated (1) · Ionis Pharmaceuticals, Inc. (1) · Laval University (1) · Radboud University Medical Center (1) · Sanofi (1) · Sarepta Therapeutics, Inc. (1) · University of Versailles (1)
United States (14) · Canada (11) · United Kingdom (9) · Australia (7) · France (5) · Netherlands (5) · New Zealand (5) · Germany (4) · Italy (4) · Spain (4) · Belgium (3) · Argentina (1) · Israel (1) · South Korea (1) · Taiwan (1)
Dr. G Drost, MD, PhD (1) · Drs. B Schouwenberg, MD (1) · Drs. BC Stunnenberg, MD (1) · Drs. H Groenewoud, MSc (1) · Drs. J Raaphorst, MD (1) · Drs. J Timmermans, MD (1) · Drs. N van Alfen, MD, PhD (1) · Drs. W Woertman, PhD (1) · Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP (1) · Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM (1) · Jack J Puymirat, MD (1) · Joseph P Horrigan, MD (1) · Li Tai, MD (1)
PMID 18678823, PMID 20837825, PMID 22578232, PMID 25880166, PMID 30535218, PMID 32942085, PMID 36790141, PMID 36804094, PMID 39555632, PMID 41707138
2016 (2), 2023 (2), U54NS048843 (1)